Literature DB >> 22470678

Testicular relapse of non-Hodgkin Lymphoma noted on FDG-PET.

Stephen D Scotti1, Jennifer Laudadio.   

Abstract

Testicular relapse of leukemia and lymphoma is a well-recognized phenomenon, with testicular relapse of lymphoma being more common in the adult population and leukemia relapse being more common in the pediatric population. With the advent of F-18 fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) in the evaluation of lymphoma it is possible to evaluate testicular uptake of FDG and to detect primary testicular lymphoma or testicular relapse on the FDG-PET examination. Testicular relapse of non-Hodgkin lymphoma (NHL) detected on FDG-PET has been reported previously. We report an additional case in which there was testicular activity at presentation, a response to therapy (orchiectomy not performed) and then testicular relapse followed by orchiectomy. We review the literature with regard to testicular recurrence and testicular uptake of FDG-PET. There have been studies that have examined normal standardized uptake value maximum (SUVmax) values in the testicle, with normal values ranging from 2.81 (30-39 years) to 2.18 (80-89 years), depending upon age. However, it should be noted that there could be considerable variability in SUVmax values depending upon the units used (e.g. normalized to lean body mass vs. body weight) and depending upon examination variables such as dietary conditions, muscle uptake or extravasation of FDG. Elevated activity or lateralizing activity should be viewed with suspicion, with etiologies including primary testicular tumor, primary or secondary testicular lymphoma and metastatic disease with other etiologies less likely.

Entities:  

Keywords:  Non-Hodgkin’s Lymphoma; PET; PET/CT; testicular lymphoma

Year:  2009        PMID: 22470678      PMCID: PMC3303329          DOI: 10.3941/jrcr.v3i8.242

Source DB:  PubMed          Journal:  J Radiol Case Rep        ISSN: 1943-0922


  5 in total

Review 1.  An oncological view on the blood-testis barrier.

Authors:  Joost Bart; Harry J M Groen; Winette T A van der Graaf; Harry Hollema; N Harry Hendrikse; Willem Vaalburg; Dirk T Sleijfer; Elisabeth G E de Vries
Journal:  Lancet Oncol       Date:  2002-06       Impact factor: 41.316

2.  Testicular involvement in leukemia and lymphoma.

Authors:  R L Givler
Journal:  Cancer       Date:  1969-06       Impact factor: 6.860

3.  Normal uptake of 18F-FDG in the testis: an assessment by PET/CT.

Authors:  Kazuhiro Kitajima; Yuji Nakamoto; Michio Senda; Yumiko Onishi; Hiromi Okizuka; Kazuro Sugimura
Journal:  Ann Nucl Med       Date:  2007-09-25       Impact factor: 2.668

4.  Non-Hodgkin's lymphoma (NHL) of the testicle. A clinicopathologic study of 19 patients.

Authors:  J Rojo; V Sales; A Paredes; J Soriano
Journal:  In Vivo       Date:  1991 May-Jun       Impact factor: 2.155

Review 5.  Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.

Authors:  Einat Even-Sapir; Genady Lievshitz; Chava Perry; Yair Herishanu; Hedva Lerman; Ur Metser
Journal:  Radiol Clin North Am       Date:  2007-07       Impact factor: 2.303

  5 in total
  1 in total

1.  Utility of FDG PET/CT in the Management of Primary Testicular Lymphoma.

Authors:  Kürşat Okuyucu; Semra İnce; Engin Alagöz; Erman Ataş; Nuri Arslan
Journal:  Mol Imaging Radionucl Ther       Date:  2018-06-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.